There are 2867 resources available
1222P - Predictiveness of Mandard score on recurrence patterns of esophageal adenocarcinoma after neoadjuvant therapy and surgery
Presenter: Dajia Liu
Session: Poster session 16
1223P - First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in
Presenter: Kohei Shitara
Session: Poster session 16
1224P - Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08)
Presenter: Yu Sunakawa
Session: Poster session 16
1226P - Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay
Presenter: Caroline Fong
Session: Poster session 16
1227P - Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
Presenter: Samuel Cytryn
Session: Poster session 16
1228P - Stage migration, changed treatment profile and survival impact in newly diagnosed oesophago-gastric cancer in Scotland during the COVID-19 pandemic: A national study
Presenter: Mark Baxter
Session: Poster session 16
1229P - A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers
Presenter: Andrew Ko
Session: Poster session 16
1230P - Immunotherapies for gastric cancer with CLDN18-ARHGAP fusion gene
Presenter: Yue Wang
Session: Poster session 16